
Eaton agrees to acquire COL Group for €810M in European power deal
COL forecasts €250 million in 2027 sales; Eaton expects the acquisition to close in the first quarter, subject to approvals.

The Sept. 25 weekly update lists 288.1 BTC mined and zero net coins added; Friday's Nasdaq close predates the post.

COL forecasts €250 million in 2027 sales; Eaton expects the acquisition to close in the first quarter, subject to approvals.

The application seeks dosing for smaller children with APDS, and the FDA set Jan. 30, 2027 as its target action date.
Its July placement issued 35.98 million shares and matching warrants, while the latest notice disclosed $334,577 in finder fees.
The Czech supplier must develop an SMR prototype before global deliveries; the current award's price and shipment date were not released.

Mirum expects U.S. availability in October after a 63-patient study; its prespecified new-lesion incidence endpoint missed the conventional threshold.

In the 257-person pivotal cohort, 42 per cent on 4 mg reached the scalp hair endpoint at Week 36, against 5 per cent on placebo.

The Swedish developer says the deal could bring up to €1.165B, but its published terms do not separate the upfront payment from later milestones.

The partners cited FDA discussions over Phase 2 evidence and kept a randomized Phase 3 lung cancer trial enrolling.
The Swiss cybersecurity group expects Oct. 2 to be the last session for its existing ADSs and Class B shares before a planned WISeQey listing.
Holders will weigh a new parent company, a Delaware move and a voting-share sunset extension as Cresco pursues a potential U.S. listing.
A Sept. 24 federal notice opens intervention in Transco's Pennsylvania pipeline application, while Williams targets late 2027 service.
Curaleaf urged a signature on Sept. 23; A10698B would let regulators seek suspensions and impose daily civil penalties.
A CAD administration role accounts for US$57,127 of the forecast; a US$3.43M ten-year value depends on continued authorization.
It counted 180 new customer contracts through Sept. 23 but gave no schedule for recognizing their value as revenue.
The three-year Saudi program can run two years longer, but SLB did not disclose a contract value or a first-well date.
Gold, silver, uranium, lithium, copper and rare earths: the producers, the developers and the projects behind them.
View all
The US$3.65 units carry half a warrant each, and Goldgroup has not assigned the proceeds to specific projects.
Medical and pharmaceutical developments, psychedelics, and the research and safety questions around them.
View all
The small ALTITUDE follow-up lacks a control comparison; the dose is being tested in the sham-controlled NAAVIGATE trial.
Technology, computing, crypto and cannabis, and the listed companies moving in them.
View all
Rexel plans about €800M in cash and debt and may raise up to €500M in equity before a targeted 2026 year-end close.
The seven-year CPU services agreement carries delivery conditions, a preferred-share warrant and a projected late 2027 service start.
Uranium, lithium, oil and gas, hydrogen and the grid: the fuels and the companies behind them.
View all
June-quarter sales fell to about US$13,500, while a post-year-end secured loan added US$20 million in initial funding.

PEJ aims to finish negotiations by year-end 2026 for three AP1000 units totaling 3,750 MWe; the EPC price remains undisclosed.

The Sept. 21 term sheet mixes direct investment and engineering services, requires approvals and leaves Samsung's cash share and equity stake undisclosed.
Licensed producers, retail, policy, and the psychedelics companies moving through the clinic.
View all
Aurora cites missing pro forma financials, a French-language notice and the mandatory 105-day deposit period in its ASC application.

Advisers voted 10 to 0 on safety and 6 to 4 on effectiveness; the FDA has not set a date for its final decision.

A 51 per cent stake in a Polish drone company remains a non-binding proposal, while the registered share sale is expected to close Sept. 24.

The Health Canada-authorized depression study plans to enroll up to 200 people, while the batch also serves Australian clinics.